Q-omics provides the consensus-scored PRELID3BP4 profile across patient tissues and cancer cell-line models. PRELID3BP4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PRELID3BP4 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, PRELID3BP4 RNA expression shows 8,102 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, HNSC, and THYM as cancer lineages where PRELID3BP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRELID3BP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRELID3BP4 survival associations across molecular data types. PRELID3BP4 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRELID3BP4 RNA expression–survival associations across cancer types. High PRELID3BP4 expression shows unfavorable associations in KIRP, LIHC, LGG and READ, but favorable associations in HNSC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for PRELID3BP4 RNA expression.
This table summarizes PRELID3BP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PRELID3BP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRELID3BP4 shows lower tumor expression in BRCA and higher tumor expression in HNSC, KIRC, LUAD, LIHC and THCA. The HNSC box plot shows higher PRELID3BP4 RNA expression in tumor versus normal tissue (log2 FC = +0.091, t-test p = .001).
This table shows molecular features associated with PRELID3BP4 in patient tissues and cancer cell lines. In patient samples, PRELID3BP4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
